Premier (PINC) Leerink’s Global Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
Leerink’s Global Healthcare Conference 2025 summary
18 Dec, 2025Industry and market dynamics
Health systems face uncertainty from potential Medicaid and Medicare cuts and changes to NIH cost reimbursement, especially impacting academic centers.
Executives are seeking disruptive transformation and total value creation, not just incremental improvements.
Financial pressures are driving increased interest in clinical standardization and shared services.
Labor shortages and retirements are accelerating the need for technology-driven labor extenders.
Strategic initiatives and technology investments
Expanding Surpass and Ascend programs to increase contract penetration from 20-25% to 50-75%.
Technology investments focus on automating supply chain processes, invoice management, and value analysis.
AI and machine learning are used for prior authorization, coding, documentation, and patient trial identification.
Shared services and co-management models are being developed to drive efficiency and scale.
Financial performance and contract momentum
Supply chain services are outperforming expectations, with 5% year-to-date growth in gross administrative fees.
New contract wins, such as AllSpire, are ramping up and expected to boost future performance.
Contract penetration and compliance are key growth drivers, with significant untapped opportunities in purchase services and physician preference items.
Fee share restructuring is nearing completion, providing stability and supporting future growth.
Latest events from Premier
- Q4 revenue up 3%, FY25 guidance targets $1.02B revenue, $1.28 EPS, excluding divestitures.PINC
Q4 202423 Jan 2026 - Q1 net income rose to $72.9M on $248.1M revenue, driven by a $57M legal settlement.PINC
Q1 202516 Jan 2026 - Technology-driven growth, new leadership, and capital returns support long-term value.PINC
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q2 loss driven by $126.8M impairment; guidance reaffirmed, adjusted EPS outlook raised.PINC
Q2 20259 Jan 2026 - Definitive merger agreement for $28.25/share cash buyout, board-approved, pending shareholder vote.PINC
Proxy Filing1 Dec 2025 - Shareholders to vote on $28.25 per share all-cash merger, board unanimously recommends approval.PINC
Proxy Filing1 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong ESG focus.PINC
Proxy Filing1 Dec 2025 - Shareholders to vote on a $28.25 per share all-cash merger, unanimously backed by the board.PINC
Proxy Filing1 Dec 2025 - Acquisition by Patient Square Capital will take the company private, pending approvals.PINC
Proxy Filing1 Dec 2025